Catalent Pharma Solutions, Inc., a provider of advanced technologies and outsourced services to the global pharmaceutical, biotechnology and consumer health industry, has received notice that the FDA has approved the sale of a prescription product manufactured in Catalent’s recently opened, state-of-the-art pre-filled syringe facility in Brussels, Belgium. Syringes from Catalent’s Brussels facility will likely be dispensed to patients in the United States in upcoming months. Richard Yarwood, group president of Catalent’s Sterile Technologies segment, said, “We are very pleased to have reached this important milestone in the evolution of our Brussels facility, and to further extend our strategic partnership with this customer. With this first FDA product approval, we even more strongly positioned to help our customers satisfy the fast growing U.S. market demand for drugs and biologics in prefilled syringe format.”
